RxDoctor Payments Data

Vivianne Beyer, MD

Dermatology · Springfield, ILNPI 1619110038

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $619 of the $996 with a category attached, or 62.1%. 10 manufacturers reported payments, led by AbbVie at 31.3% of the total. 2025 is the largest year on record at $381, 3.9 times the $98 reported in 2019. That places this record below the midpoint for dermatology clinicians in IL, where the typical reported total is $1,774.

$996in general payments, 2019–2025

Across 31 payments — averaging $32.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$312
  • Sun Pharmaceutical Industries Inc.$228
  • Johnson & Johnson$213
  • Amgen$68
  • Lilly USA, LLC$49
  • Regeneron Healthcare Solutions, Inc.$32
  • plus $96 from 4 others
$392,459in research payments, 2019–2025

Across 15 payments — averaging $26,164 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$392K

What the payments were for

  • Food & beverage$61962%
  • Education$37838%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$996 in reported general payments places this provider in the 35th percentile of 606 dermatology providers in Illinois.

See all dermatology providers in Illinois

Medicare billing

Part B allowed, 2024
$233,421
Medicare patients
897
Services billed
4,803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab52$194,796
OtezlaApremilast24$174,210
Cimzia (2 Pack)Certolizumab Pegol15$169,666
RinvoqUpadacitinib23$145,008
Humira(Cf)Adalimumab12$81,410
Clobetasol Propionate237$10,376
Fluorouracil58$4,824
Ketoconazole311$4,529
Metronidazole59$3,239
Doxycycline Hyclate106$3,063
Tacrolimus37$2,313
Desonide46$1,951
Triamcinolone Acetonide184$1,752
Dapsone18$1,666
Clindamycin Phosphate45$1,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$312$226,41835 claims
AmgenOtezla$68$174,21024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 606 dermatology providers in Illinois.

Other dermatology in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →